New data for Arexvy, GSK’s respiratory syncytial virus vaccine, …
Oct 24, 2024 · GSK plc (LSE/NYSE: GSK) today announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased …
Arexvy Looks Promising for RSV Protection in Younger At-Risk …
Nov 4, 2024 · Arexvy is currently approved for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 60 years of age and older, and …
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
The FDA has approved Arexvy, the first RSV vaccine approved for use in the U.S. Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 …
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, …
PHILADELPHIA, October 24, 2024 -- (BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, …
GSK presents positive data for AREXVY, its respiratory syncytial …
Oct 8, 2024 · AREXVY is the world’s first RSV vaccine and was approved based on exceptional efficacy in adults aged 60 and older including those who are at increased risk due to certain …
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, …
Oct 24, 2024 · New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease. Single …
GSK presents positive data for Arexvy, its respiratory syncytial …
Oct 8, 2024 · GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy of a single dose of Arexvy …
US FDA approves GSK’s AREXVY, the world’s first respiratory …
May 3, 2023 · US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and …
About Arexvy (respiratory syncytial virus vaccine, adjuvanted) - GSK
Jun 21, 2023 · GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy of a single dose of …
GSK shares positive data for AREXVY, its respiratory syncytial virus ...
Jun 21, 2023 · New results from the ongoing AReSVi-006 phase III trial show vaccine efficacy against RSV-lower respiratory tract disease and severe disease over two full RSV seasons, …